Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathon Golas

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Journal of Visualized Experiments : Jove|April 7, 2020
Multidimensional Coculture System to Model Lung Squamous Carcinoma ProgressionShuang Chen, Andreas Giannakou, Jonathon Golas, et al.
Journal of Proteome Research|September 1, 2022
Evaluation of EDB Fibronectin in Plasma, Patient-Derived Xenograft Formalin-Fixed Paraffin-Embedded and Fresh Frozen Tumor Tissues Using Immunoaffinity LC-MS/MSFengping Li, Andrea T Hooper, Jonathon Golas, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 30, 2018
Cancer-associated fibroblasts suppress SOX2-induced dysplasia in a lung squamous cancer cocultureShuang Chen, Andreas Giannakou, Sarah Wyman, et al.
Science Advances|January 21, 2026
Optimally engineered HLA/peptide-specific CAR-T cells outperform TCR-T cells to eradicate solid tumorsCorinne E Decker, Jacqueline Idun, Katja Mohrs, et al.
Oncotarget|February 12, 2015
Epigenetic reprogramming by tumor-derived EZH2 gain-of-function mutations promotes aggressive 3D cell morphologies and enhances melanoma tumor growthAnthony M Barsotti, Michael Ryskin, Wenyan Zhong, et al.
Molecular Cancer Therapeutics|December 11, 2012
Long-term tumor regression induced by an antibody-drug conjugate that targets 5T4, an oncofetal antigen expressed on tumor-initiating cellsPuja Sapra, Marc Damelin, John Dijoseph, et al.
The EMBO Journal|May 17, 2015
Reciprocal regulation of amino acid import and epigenetic state through Lat1 and EZH2Stephen G Dann, Michael Ryskin, Anthony M Barsotti, et al.
Cell Reports. Medicine|June 7, 2021
NOTCH3-targeted antibody drug conjugates regress tumors by inducing apoptosis in receptor cells and through transendocytosis into ligand cellsKenneth G Geles, Yijie Gao, Andreas Giannakou, et al.
Molecular Cancer Therapeutics|July 6, 2022
Anti-Extra Domain B Splice Variant of Fibronectin Antibody-Drug Conjugate Eliminates Tumors with Enhanced Efficacy When Combined with Checkpoint BlockadeAndrea T Hooper, Kimberly Marquette, Chao-Pei Betty Chang, et al.
Molecular Cancer Therapeutics|August 5, 2020
PF-06804103, A Site-specific Anti-HER2 Antibody-Drug Conjugate for the Treatment of HER2-expressing Breast, Gastric, and Lung CancersEdmund I Graziani, Matthew Sung, Dangshe Ma, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Journal of Visualized Experiments : Jove|April 7, 2020
Multidimensional Coculture System to Model Lung Squamous Carcinoma ProgressionShuang Chen, Andreas Giannakou, Jonathon Golas, et al.
Journal of Proteome Research|September 1, 2022
Evaluation of EDB Fibronectin in Plasma, Patient-Derived Xenograft Formalin-Fixed Paraffin-Embedded and Fresh Frozen Tumor Tissues Using Immunoaffinity LC-MS/MSFengping Li, Andrea T Hooper, Jonathon Golas, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 30, 2018
Cancer-associated fibroblasts suppress SOX2-induced dysplasia in a lung squamous cancer cocultureShuang Chen, Andreas Giannakou, Sarah Wyman, et al.
Science Advances|January 21, 2026
Optimally engineered HLA/peptide-specific CAR-T cells outperform TCR-T cells to eradicate solid tumorsCorinne E Decker, Jacqueline Idun, Katja Mohrs, et al.
Oncotarget|February 12, 2015
Epigenetic reprogramming by tumor-derived EZH2 gain-of-function mutations promotes aggressive 3D cell morphologies and enhances melanoma tumor growthAnthony M Barsotti, Michael Ryskin, Wenyan Zhong, et al.
Molecular Cancer Therapeutics|December 11, 2012
Long-term tumor regression induced by an antibody-drug conjugate that targets 5T4, an oncofetal antigen expressed on tumor-initiating cellsPuja Sapra, Marc Damelin, John Dijoseph, et al.
The EMBO Journal|May 17, 2015
Reciprocal regulation of amino acid import and epigenetic state through Lat1 and EZH2Stephen G Dann, Michael Ryskin, Anthony M Barsotti, et al.
Cell Reports. Medicine|June 7, 2021
NOTCH3-targeted antibody drug conjugates regress tumors by inducing apoptosis in receptor cells and through transendocytosis into ligand cellsKenneth G Geles, Yijie Gao, Andreas Giannakou, et al.
Molecular Cancer Therapeutics|July 6, 2022
Anti-Extra Domain B Splice Variant of Fibronectin Antibody-Drug Conjugate Eliminates Tumors with Enhanced Efficacy When Combined with Checkpoint BlockadeAndrea T Hooper, Kimberly Marquette, Chao-Pei Betty Chang, et al.
Molecular Cancer Therapeutics|August 5, 2020
PF-06804103, A Site-specific Anti-HER2 Antibody-Drug Conjugate for the Treatment of HER2-expressing Breast, Gastric, and Lung CancersEdmund I Graziani, Matthew Sung, Dangshe Ma, et al.
Pageof 2